Centre for Research in Biopharmaceuticals and Biotechnology, Department of Biology, University of Ottawa, Ottawa, ON, Canada.
Planta Med. 2011 Jan;77(2):196-204. doi: 10.1055/s-0030-1250161. Epub 2010 Aug 17.
Nonenzymatic formation of advanced glycation end products (AGEs) is accelerated under hyperglycemic conditions characteristic of type 2 diabetes mellitus and contributes to the development of vascular complications. As such, inhibition of AGE formation represents a potential therapeutic target for the prevention and treatment of diabetic complications. In the present study, ethanolic extracts of 17 medicinal plants were assessed for inhibitory effects on in vitro AGE formation through fluorometric and immunochemical detection of fluorescent AGEs and N(ε)-(carboxymethyl)lysine adducts of albumin (CML-BSA), respectively. Most extracts inhibited fluorescent AGE formation with IC (50) values ranging from 0.4 to 38.6 µg/mL and all extracts reduced CML-BSA formation but to differing degrees. Results obtained through both methods were highly correlated. Antiglycation activities were positively correlated with total phenolic content, free radical scavenging activity and reduction in malonyldiadehyde levels following oxidation of low-density lipoprotein, but negatively correlated with lag time to formation of conjugated dienes. Together, these results provide evidence that antioxidant phenolic metabolites mediate the antiglycation activity of our medicinal plant collection, a relationship that likely extends to other medicinal and food plants.
非酶糖化终产物(AGEs)的形成在 2 型糖尿病特征性的高血糖条件下加速,并促进血管并发症的发展。因此,抑制 AGE 的形成代表了预防和治疗糖尿病并发症的一个潜在治疗靶点。在本研究中,通过荧光法和免疫化学法分别检测荧光 AGEs 和白蛋白 N(ε)-(羧甲基)赖氨酸加合物(CML-BSA),评估了 17 种药用植物的乙醇提取物对体外 AGE 形成的抑制作用。大多数提取物对荧光 AGE 的形成具有抑制作用,IC(50)值范围为 0.4 至 38.6 µg/mL,所有提取物均能减少 CML-BSA 的形成,但程度不同。两种方法得到的结果高度相关。糖化抑制活性与总酚含量、自由基清除活性以及氧化型低密度脂蛋白(LDL)丙二醛水平的降低呈正相关,与共轭二烯形成的延迟时间呈负相关。综上所述,这些结果表明抗氧化酚类代谢物介导了我们药用植物提取物的糖化抑制活性,这种关系可能扩展到其他药用和食用植物。